Methods of Identifying Novel Proteins and Antigens in Cancer Cells

Contracts Guide

Disclose Your Invention
MTA/CDA Assistance
COVID-19 Related Agreements
Main Campus Research
Office of Sponsored Research
Education Links

Connect with Industry

Technologies for Licensing
Industry Collaboration Opportunities
Research and Clinical Trials

Categories: “Cancer Therapeutics

Reference #: 2017-002

OTC Contact: Ruchika Nijhara, PhD, MBA, CLP (Directory Information | Send a Message)


A technique that employs single molecule real time (SMRT) sequencing to uncover aberrant RNA splice variants that are characteristic of cancer cell splice transcripts – sequencing of such splice variants results in predictable protein epitopes that can be targeted for treatment.

Aberrant splicing of pre-mRNA in cancer cells generates multiple transcripts, which are ultimately translated into disjointed proteins thus revealing novel protein junctions. The exposed junctions act as neo-epitopes that can be recognized by the immune system.



Stage of Development

Technique has validated been human bone marrow cell subpopulations, revealing novel mRNA isoforms.
Researchers are assessing applicability to aberrant cancer cell transcription.

Patent Status

Provisional application has been filed.